68Ga-DOTATOC-PET/MRI and 11C-5-HTP-PET/MRI are superior to 68Ga-DOTATOC-PET/CT for neuroendocrine tumour imaging

被引:15
|
作者
Jawlakh, Hiba [1 ]
Velikyan, Irina [1 ]
Welin, Staffan [2 ]
Sundin, Anders [1 ]
机构
[1] Uppsala Univ, Dept Surg Sci Radiol & Mol Imaging, Uppsala, Sweden
[2] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
关键词
C-11-5-HTP; Ga-68-DOTATOC; detection rate; neuroendocrine tumour; PET/CT; PET/MRI; SUVmax; tumour-to-background ratio; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; POSITRON-EMISSION-TOMOGRAPHY; ENETS CONSENSUS GUIDELINES; CONTRAST-ENHANCED CT; GA-68-DOTA-TYR(3)-OCTREOTIDE PET; BONE METASTASES; PET/MRI; MANAGEMENT; DIAGNOSIS; DOTATOC;
D O I
10.1111/jne.12981
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The present study aimed to assess gadoxetate disodium contrast-enhanced (CE) positron emission tomography (PET)/magnetic resonance imaging (MRI) with Ga-68-DOTATOC and C-11-5-Hydroxy-tryptophan (C-11-5-HTP) in comparison with iodine CE Ga-68-DOTATOC-PET/computed tomography (CT) for neuroendocrine tumour imaging. Detection rate and reader's confidence were evaluated for each separate image volume: CE-CT, CE-MRI including diffusion-weighted imaging, Ga-68-DOTATOC-PET performed at PET/CT, Ga-68-DOTATOC-PET performed at PET/MRI and C-11-5-HTP-PET, and for the three combined hybrid examinations Ga-68-DOTATOC-PET/MRI, C-11-5-HTP-PET/MRI and Ga-68-DOTATOC-PET/CT. In 11 patients, 255 lesions were depicted. Ga-68-DOTATOC-PET performed at PET/MRI depicted 72.5%, Ga-68-DOTATOC-PET performed at PET/CT depicted 62.7%, C-11-5-HTP-PET depicted 68.2% and CE-CT depicted 53% of lesions. Ga-68-DOTATOC-PET performed at PET/MRI (P < 0.001) and PET/CT (P = 0.02), C-11-5-HTP-PET (P < 0.001) and MRI (P < 0.001) were superior to CT. Ga-68-DOTATOC-PET/MRI and C-11-5-HTP-PET/MRI detected 92.5% and 92% of lesions, respectively, and both outperformed Ga-68-DOTATOC-PET/CT (65%) (P < 0.001). For liver metastasis imaging, MRI alone was unsurpassed (P < 0.01) and Ga-68-DOTATOC-PET/MRI and C-11-5-HTP-PET/MRI outperformed Ga-68-DOTATOC-PET/CT (P < 0.001). For lymph node metastasis diagnosis, Ga-68-DOTATOC-PET performed at PET/MRI and PET/CT and C-11-5-HTP-PET detected 94%, 94% and 94% of lesions, respectively, and outperformed MRI and CE-CT alone (P < 0.001). For bone metastasis imaging, Ga-68-DOTATOC-PET performed at PET/MRI and PET/CT and C-11-5-HTP-PET performed equally well (P = 0.05) and better than MRI. Reader's confidence was better for Ga-68-DOTATOC-PET/MRI and C-11-5-HTP-PET/MRI than for Ga-68-DOTATOC-PET/CT. The tumour maximum standardised uptake value and tumour-to-liver ratio were both approximately twice as high as for Ga-68-DOTATOC than for C-11-5-HTP. Ga-68-DOTATOC-PET/MRI and C-11-5-HTP-PET/MRI provided the highest detection rates and reader's confidence and were both superior to Ga-68-DOTATOC-PET/CT, mainly because of the MRI component. The imaging contrast with Ga-68-DOTATOC was superior to that of C-11-5-HTP.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Fully hybrid 68Ga-DOTATOC PET/MRI in NET patients: synergic value of 68Ga-DOTATOC PET and MRI
    Mapelli, Paola
    Ironi, Gabriele
    Partelli, Stefano
    Fallanca, Federico
    Muffatti, Francesca
    Andreasi, Valentina
    Scifo, Paola
    Bettinardi, Valentino
    Rigamonti, Riccardo
    Savi, Annarita
    Gianolli, Luigi
    Falconi, Massimo
    De Cobelli, Francesco
    Picchio, Maria
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [22] Rare metastases diagnosed on 68Ga-DOTATOC-PET/CT in small intestinal and pancreatic NETs
    Wedin, M.
    Daskalakis, K.
    Wallin, G.
    Sundin, A.
    Janson, Tiensuu E.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 116 - 116
  • [23] 68Ga-DOTATOC PET/MRI for characterization of undetermined upper abdominal tracer uptake in 68Ga-DOTATOC PET/CT
    Sabet, A.
    Cohnen, J.
    Beiderwellen, K.
    Ezziddin, S.
    Umutlu, L.
    Grafe, H. V.
    Bockisch, A.
    Poeppel, T. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S234 - S234
  • [24] 68Ga-DOTATOC-PET/CT in neuroendocrine tumours: Is an additional bone scan necessary for detection of skeletal metastases?
    Oeksuez, M. O.
    Aschoff, P.
    Kemke, B.
    Rauch, D.
    Zhernosekov, K.
    Jennwein, M.
    Roesch, F.
    Zoller, W. G.
    Bihl, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2005, 32 : S158 - S158
  • [25] Synergic Value of 68Ga-DOTATOC PET and MRI in NET Patients Undergoing Simultaneous 68Ga-DOTATOC PET/MRI Scan
    Mapelli, P.
    Ironi, G.
    Partelli, S.
    Andreasi, V
    Muffatti, F.
    Bettinardi, V
    Scifo, P.
    Fallance, F.
    Gianolli, L.
    Falconi, M.
    De Cobelli, F.
    Picchio, M.
    NEUROENDOCRINOLOGY, 2020, 110 : 265 - 265
  • [26] Comparison of Contrast-enhanced MRI versus 68Ga-DOTATOC-PET/CT in Patients with Suspected Cardiac Involvement of Sarcoidosis
    Gaertner, F. C.
    Schlesinger-Irsch, U.
    Pizarro, C.
    Reiter, T.
    Skowasch, D.
    Bauer, W. R.
    Thomas, D.
    Bundschuh, R. A.
    Lapa, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S60 - S60
  • [27] Clinical efficacy of dual-phase scanning using 68Ga-DOTATOC-PET/CT in the detection of neuroendocrine tumours
    Nakamoto, Y.
    Ishimori, T.
    Sano, K.
    Temma, T.
    Ueda, M.
    Saji, H.
    Togashi, K.
    CLINICAL RADIOLOGY, 2016, 71 (10) : 1069.e1 - 1069.e5
  • [28] 68Ga-DOTATOC-PET/CT-guided resection of a primary intraosseous meningioma: technical note
    Guinto-Nishimura, Gerardo Y.
    Gomez-Amador, Juan L.
    Kerik-Rotenberg, Nora
    Uribe-Pacheco, Rodrigo
    Sangrador-Deitos, Marcos, V
    Martinez-Manrique, Jose J.
    NEUROSURGICAL FOCUS, 2021, 50 (01) : 1 - 7
  • [29] Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue
    Giesel, F. L.
    Stefanova, M.
    Schwartz, L. H.
    Afshar-Oromieh, A.
    Eisenhut, M.
    Haberkorn, U.
    Kratochwil, C.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 57 (02): : 171 - 176
  • [30] Splenic scintigraphy for further differentiation of unclear 68Ga-DOTATOC-PET/CT findings: Strengths and limitations
    Werner, Christoph
    Winkens, Thomas
    Freesmeyer, Martin
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2016, 60 (03) : 365 - 369